Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 5Terminated 3Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 29Carcinoma, Renal Cell 18Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 10Brain Neoplasms 7Skin Neoplasms 6Neoplasm Metastasis 6Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Mesothelioma 3Liver Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Ipilimumab × Clear all
NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

ModernaTX, Inc.

Phase 1/2 Recruiting
361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Chinese PLA General Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡